Novartis Group announced today that Remibutinib's phase III trial of REMODEL-1/-2 for relapsing multiple sclerosis has achieved positive top-line results. Remibutinib is a highly selective and highly effective oral Bruton tyrosine kinase inhibitor; compared with teriflunomide, it shows excellent efficacy in reducing the annual recurrence rate and inflammatory brain lesions, and also has good safety characteristics. The results of the REMODEL trial showed that in two phase III trials for adults with recurrent multiple sclerosis, remibutinib significantly reduced the annualized recurrence rate.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.